ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

palbociclib

Also written as “Palbociclib”, “PD-0332991” and “Palbociclib 125mg”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Renal Cell · Sarcoma, Ewing · Squamous Cell Carcinoma of Head and Neck · COVID-19, led by 7 companies.

Drug pagePalbociclib: every studyMany companies study it; this page follows only the 35 they lead. All 225 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 22, 201635 company-led studies, 4 open or runningNext primary completion: Dec 22, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer291 open or runningphase 4since Jan 22, 2016Aug 30, 2005Dec 31, 2029phase 2 · NCT05226871
biotx.aiits history only10 open or runningphase 2since Apr 26, 2022Apr 26, 2022none ahead
Criteriumits history only11 open or runningphase 2since Sep 3, 2020Sep 3, 2020Dec 31, 2027phase 2 · NCT04567420
CSPC Pharmaceutical Groupits history only11 open or runningphase 1since Apr 16, 2025Apr 16, 2025Oct 2027phase 1 · NCT06941142
iOMEDICOits history only10 open or runningphase 2since Aug 25, 2016Aug 25, 2016none ahead
Megalabsits history only10 open or runningphase 4since Mar 19, 2024Mar 19, 2024none ahead
Merckits history only11 open or runningphase 2since Jul 18, 2022Jul 18, 2022Dec 22, 2026phase 2 · NCT05468697

Also a collaborator on its studies: AstraZeneca and Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Aug 30, 2005.

  1. Feb 7, 2014Phase 1 study in HealthyNCT02059330 · 27 enrolled · United States
  2. Mar 11, 2014Phase 1 study in Renal InsufficiencyNCT02085538 · 31 enrolled · United States
  3. May 2, 2014Phase 1 study in HealthyNCT02131298 · 12 enrolled · United States
  4. Aug 19, 2014Phase 1 study in HealthyNCT02222441 · 14 enrolled · United States
  5. Nov 19, 2014Phase 3 study in Breast NeoplasmsNCT02297438 · 340 enrolled · China, Hong Kong, Singapore and more
  6. Dec 4, 2014Phase 1 study in HealthyNCT02311946 · 60 enrolled · United States
  7. Jan 6, 2015Phase 1 study in Hepatic InsufficiencyNCT02334800 · 28 enrolled · United States
  8. Jul 13, 20152 phase 1 studiesNCT02499146, NCT02501902
  9. Jul 13, 2015Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT02499120 · 125 enrolled · United States, Czechia, Hungary and more
  10. Nov 6, 2015Phase 3 study in Breast NeoplasmsNCT02600923 · 131 enrolled · Argentina, Brazil, Colombia and more
  11. Jan 22, 2016Phase 4 study in Breast NeoplasmsNCT02679755 · 252 enrolled · Australia, India
  12. Jun 16, 2017Phase 1 study in Healthy VolunteerNCT03220191 · 12 enrolled · United States
  13. Oct 9, 2018Phase 2 study in Sarcoma, EwingNCT03709680 · 128 enrolled · United States, Brazil, Canada and more
  14. Jan 26, 2022Phase 2 study in Breast NeoplasmsNCT05226871 · 35 enrolled · United States, China, Mexico and more

Ahead

  1. Dec 31, 2029Primary completion: phase 2 study in Breast NeoplasmsNCT05226871

TargetBeta

“CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor”ChEMBL 37, by rule

Studies

All 29 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05226871Breast Neoplasms · United States, China, Mexico and more2Active, not recruitingDec 31, 202935
NCT03709680Sarcoma, Ewing · United States, Brazil, Canada and more2CompletedAug 26, 2024128
NCT03220191Healthy Volunteer · United States1CompletedSep 3, 201712
NCT02679755Breast Neoplasms · Australia, India4CompletedJul 25, 2019252
NCT02600923Breast Neoplasms · Argentina, Brazil, Colombia and more3CompletedMay 28, 2019131
NCT02501902Metastatic Pancreatic Ductal Adenocarcinoma · United States, Spain1CompletedOct 10, 201876
NCT02499146Advanced Breast Cancer · China1CompletedJul 31, 201826
NCT02499120Squamous Cell Carcinoma of Head and Neck · United States, Czechia, Hungary and more2CompletedJul 19, 2018125
NCT02334800Hepatic Insufficiency · United States1CompletedOct 9, 201628
NCT02311946Healthy · United States1CompletedApr 201560
NCT02297438Breast Neoplasms · China, Hong Kong, Singapore and more3CompletedAug 31, 2020340
NCT02222441Healthy · United States1CompletedDec 201414
NCT02131298Healthy · United States1CompletedJun 201412
NCT02085538Renal Insufficiency · United States1CompletedMay 201631
NCT02059330Healthy · United States1CompletedJun 201427
NCT01953731Healthy · United States1CompletedJan 201415
NCT01942135Breast Neoplasms · United States, Australia, Belgium and more3CompletedDec 5, 2014521
NCT01918176Healthy · United States1CompletedDec 201326
NCT01906125Healthy · United States1CompletedJan 201473
NCT01821066Healthy · United States1CompletedAug 201325
NCT01802476Healthy · United Kingdom1CompletedJun 201314
NCT01756781Healthy · United States1CompletedJul 201326
NCT01740427Breast Neoplasms · United States, Australia, Belgium and more3CompletedFeb 26, 2016666
NCT01684215Neoplasms · Japan2CompletedMar 4, 201661
NCT01602887Breast Neoplasms · United States1CompletedNov 201224
NCT00721409Breast Neoplasms · United States, Canada, France and more2CompletedNov 29, 2013177
NCT00555906Multiple Myeloma · United States, Czech Republic, Germany2CompletedAug 201253
NCT00420056Lymphoma, Mantle-Cell · United States1CompletedMar 201017
NCT00141297Neoplasms · United States1CompletedJul 200874

How it is read

Names in the registry

  • “Palbociclib”, 16 entries
  • “PD-0332991”, 12 entries
  • “palbociclib”, 5 entries
  • “Palbociclib 125mg”, 3 entries
  • “Palbociclib alone”, 3 entries

Codes read as this program: PD0332991.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.